Helus Pharma has appointed Dr. Suresh Durgam to its Board of Directors. Dr. Durgam, a CNS drug development expert with over 20 years of experience, previously served on Helus Pharma’s Scientific Advisory Board and played key roles in FDA approvals for CNS therapies. His addition is expected to strengthen Helus Pharma’s clinical, regulatory, and commercial efforts as it advances its serotonergic agonist drug pipeline targeting mental health conditions. The appointment awaits Cboe Canada approval.
Helus Pharma's recent board appointment is noted alongside Pluang's health sector market data. Of 150 priced health-sector US stocks on Pluang, 93 rose and 47 fell today. As of Oct 15, 2026 17:42 WIB, Ascendis Pharma A/S (ASND) traded at USD 219.09 with a 1-day change of -3.48%, Aurora Cannabis Inc (ACB) at USD 4.03 with -3.36%, and Axogen Inc (AXGN) at USD 33.97 with -3.33%.
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
Nokia has transferred 2,142,361 of its own shares to employees participating in its stock-based incentive programs, as per a board decision announced in October 2025. This transfer was made without compensation and is part of fulfilling commitments u...
Pallavi Mahajan, a senior manager at Nokia Corporation, received 35,192 shares through a share-based incentive on October 15, 2026. This transaction was reported under EU Market Abuse Regulation, reflecting Nokia's ongoing use of equity incentives to...
